Chronic kidney disease enhances alternative pathway activity: a new paradigm
Journal of Clinical Investigation · 01.05.2025 · 135 (9)
DOI: 10.1172/jci188353 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.05.2025. Verfasst von Diana I Jalal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Complement Pathway, Alternative. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Reduced kidney function is associated with increased risk of cardiovascular disease in addition to kidney disease progression. Kidney disease is considered an inflammatory state, based on elevated levels of C-reactive protein and inflammatory cytokines. A key mediator of cardiovascular and kidney disease progression in the setting of reduced kidney function is systemic and vascular inflammation. However, the exact pathways that link chronic kidney disease (CKD) with inflammation remain incompletely understood. For decades it has been known that factor D, the main activator of the alternative complement pathway, is increased in the plasma of patients with reduced kidney function. Recent biomarker evidence suggests alternative pathway activation in this setting. CKD, therefore, seems to alter the balance of alternative pathway proteins, promoting inflammation and potentially exacerbating complement-mediated diseases and CKD-associated complications. In this manuscript, we review the impact of reduced kidney function on biomarkers of the alternative complement pathway and the implications of alternative pathway activation on cardiovascular disease and kidney disease progression. Importantly, we highlight the need for ongoing research efforts that may lead to opportunities to target the alternative pathway of complement withx the goal of improving kidney and cardiovascular outcomes in persons with reduced kidney function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.
- Center for Access and Delivery Research and Evaluation, Iowa City VA Health Care System, Iowa City, Iowa, USA.
- Division of Renal Diseases and Hypertension, Department of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, Colorado, USA.
- Molecular Otolaryngology and Renal Research Laboratories, University of Iowa, Iowa City, Iowa, USA.
Förderung
- NIDDK NIH HHS
Zitieren
APA
Jalal, D. I., Thurman, J. M., & Smith, R. J. (2025). Chronic kidney disease enhances alternative pathway activity: a new paradigm. Journal of Clinical Investigation, 135(9). https://doi.org/10.1172/jci188353
Vancouver
Jalal DI, Thurman JM, Smith RJ. Chronic kidney disease enhances alternative pathway activity: a new paradigm. Journal of Clinical Investigation. 2025;135(9). doi:10.1172/jci188353
BibTeX
@article{Jalal2025,
author = {Jalal, Diana I and Thurman, Joshua M and Smith, Richard Jh},
title = {Chronic kidney disease enhances alternative pathway activity: a new paradigm},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {9},
doi = {10.1172/jci188353}
}
EUVIMED